PTC Therapeutics, Inc. , a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders.
Ptc Therapeutics stock last closed at $49.84, up 0.65% from the previous day, and has increased 55.02% in one year. It has overperformed other stocks in the Biotechnology industry by 1.32 percentage points. Ptc Therapeutics stock is currently +73.54% from its 52-week low of $28.72, and -14.63% from its 52-week high of $58.38.
As of Apr 30, 2025, there are 78.87M PTCT shares outstanding. The market value of PTCT is $3.93B. In the last 24 hours, 1.04M PTCT shares were traded.
You need a brokerage account to access the NASDAQ market and buy PTCT stock.
Based on our research, eToro is the best stock brokerage. eToro gives you:
Get $10 towards your share purchase by creating an account with eToro now. This offer is only for US users.
Open eToro AccountNow that you've picked the best brokerage, the next step is to fill out some personal info so you can invest in PTCT stock today.
Now that you have created your account on stock market apps, your next step is to transfer the money for your investment:
Check out the walkthrough below if you need help transferring money into your brokerage account.
Once you have figured out the best place to buy Ptc Therapeutics stock, it's critical to analyze their stock before you invest, so you actually wrap your head around the risk as well as the opportunity.
WallStreetZen was designed to help everyday investors do more in-depth fundamental analysis in less time.
You can view all of the due diligence checks on PTCT's stock page.
Investors use a variety of different financial metrics, analyses, models, and charts to gauge PTCT's true value.
You can do additional valuation research on PTCT's stock here.
Out of 12 Wall Street analysts who monitor PTCT, the consensus analyst rating on PTCT is a Buy
It's important to keep in mind that analyst ratings are not recommendations, nor are they financial advice.
David Lebovitz, a bottom 14% analyst from Citigroup maintains PTCT with a strong sell rating and raises their PTCT price target from $32.00 to $45.00, on Feb 12, 2025.
Kristen Kluska, a top 2% analyst from Cantor Fitzgerald maintains PTCT with a strong buy rating and raises their PTCT price target from $76.00 to $113.00, on Feb 3, 2025.
Cantor Fitzgerald's Kristen Kluska raised their price target on Ptc Therapeutics (NASDAQ: PTCT) by 48.7% from $76 to $113 on 2025/02/03. The analyst maintained their Strong Buy rating on the stock.
PTC Therapeutics has several regulatory decisions coming this year, Kluska reminded readers, saying they are very optimistic about sepiapterin, an oral precursor to enzymatic cofactor, for phenylketonuria.
The analyst said they are "incredibly bullish" on the drug's profile, arguing that it offers obvious advantages over the gold standard treatment, KUVAN.
Phenylketonuria is a rare genetic disorder that causes high levels of phenylalanine (Phe) in the blood, which can lead to intellectual disabilities and other health issues.
KUVAN is a prescription medication used to help manage Phenylketonuria.
Paul Choi, a bottom 11% analyst from Goldman Sachs maintains PTCT with a strong sell rating and raises their PTCT price target from $32.00 to $42.00, on Dec 4, 2024.
Colin Bristow, a bottom 6% analyst from UBS maintains PTCT with a strong buy rating and raises their PTCT price target from $47.00 to $71.00, on Dec 3, 2024.
Joel Beatty, a bottom 14% analyst from Baird maintains PTCT with a buy rating and raises their PTCT price target from $52.00 to $70.00, on Dec 3, 2024.
You can dive deeper into what analysts are projecting on the Ptc Therapeutics stock forecast page.
Last year, PTCT revenue was $806.78M. In the past 5 year, PTCT's revenue has increased by 21.32% per year. This was slower than the Biotechnology industry average of 45.66%.
Dig into PTCT's earnings and revenue performance here.
Over the past year, executives and large shareholders at PTCT have sold more shares than they have bought.
Matthew B. Klein, CHIEF EXECUTIVE OFFICER of PTCT, was the latest PTCT insider to sell. They sold $136,655.74 worth of PTCT stock on Apr 22, 2025.
Get more info about who owns PTCT shares here.
No, Ptc Therapeutics doesn't provide an income stream by paying out dividends.
One of the major reasons eToro is our top-rated brokerage is because of its social trading community.
Click below to see what other community members have to say.
You have two main types of orders:
Press the Open button and eToro will execute the order.
If you want additional assistance buying stocks on eToro, click the how to video below:
Now that you own some shares in PTCT, you'll want to keep up with your company.
Create a watchlist to keep tabs on your PTCT stock.
To summarize, here are the 6 steps for buying Ptc Therapeutics stock:
If you require a place to buy stocks, eToro is our favorite option.
Get Started with eToro TodayIf you would like to keep track of your investment in Ptc Therapeutics, hit the button below to create your watchlist.